• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

Major Depressive Disorder

Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform

November 7, 2022 by SharpBrains

Alto Neu­ro­science Rais­es $35M Series B Financ­ing (Fins­Mes):

Alto Neu­ro­science, a Los Altos, CA-based neu­ro-tech com­pa­ny which spe­cial­izes in pre­ci­sion psy­chi­a­try, rais­es $35M Series B Financ­ing … The com­pa­ny intends to use the funds to advance lead can­di­dates into Phase 2b stud­ies in major depres­sive dis­or­der … Pro­ceeds from the financ­ing will also be used to progress the company’s arti­fi­cial intel­li­gence-enabled brain bio­mark­er plat­form and launch new clin­i­cal tri­als in areas of high unmet med­ical need. Alto will report Phase 2a data in ear­ly 2023 and fur­ther antic­i­pates Phase 2b data read­outs by ear­ly 2024. [Read more…] about Pre­ci­sion psy­chi­a­try pio­neer Alto Neu­ro­science rais­es $35M to advance dig­i­tal bio­mark­er-to-treat­ment platform

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: Alto Neuroscience, Amit Etkin, artificial intelligence, brain biomarker, EEG activity, Major Depressive Disorder, neuro-tech, precision psychiatry

Neuromodulation device Relivion gets FDA clearance to help patients with major depression who don’t benefit from antidepressant medications

August 12, 2020 by SharpBrains

Neu­rolief wins FDA break­through nod for wear­able neu­ro­mod for depres­sion (Mass Device):

Neu­rolief announced today that it received FDA break­through device des­ig­na­tion for its Reliv­ion DP sys­tem for treat­ing major depression.

Reliv­ion is a wear­able, non-inva­sive, mul­ti-chan­nel brain neu­ro­mod­u­la­tion device designed as an adjunc­tive treat­ment to phar­ma­ceu­ti­cal man­age­ment of major depres­sive dis­or­der (MDD) in adults who haven’t expe­ri­enced sat­is­fac­to­ry improve­ment from anti­de­pres­sant med­ica­tions, accord­ing to a news release. [Read more…] about Neu­ro­mod­u­la­tion device Reliv­ion gets FDA clear­ance to help patients with major depres­sion who don’t ben­e­fit from anti­de­pres­sant medications

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: antidepressant medications, breakthrough device, depression, FDA, Major Depressive Disorder, medication, Neurolief, neuromod, neuromodulation, Psychotherapy, Relivion DP, treating major depression, treatments, wearable

Otsuka Pharma and Click Therapeutics enter partnership poised to transform mental healthcare

January 4, 2019 by SharpBrains

Otsu­ka, Click Ther­a­peu­tics part­ner to cre­ate ther­a­py for men­tal ill­ness (Ver­dict Med­ical Devices):

“Otsu­ka Pharmaceutical’s US divi­sion Otsu­ka Amer­i­ca has part­nered with Click Ther­a­peu­tics to devel­op and com­mer­cialise a pre­scrip­tion dig­i­tal ther­a­peu­tic for treat­ing major depres­sive dis­or­der (MDD) [Read more…] about Otsu­ka Phar­ma and Click Ther­a­peu­tics enter part­ner­ship poised to trans­form men­tal healthcare

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: Click Therapeutics, FDA, Major Depressive Disorder, mental healthcare, mental-illness, Otsuka, Otsuka Pharmaceutical

Transcranial Direct Current Stimulation shows early promise to ameliorate depression, especially if combined with other therapies and dosage optimized

October 1, 2018 by SharpBrains

___

Tran­scra­nial Direct Cur­rent Stim­u­la­tion Promis­ing for Major Depres­sive Dis­or­der (Psy­chi­a­try Advisor):

“Tran­scra­nial direct cur­rent stim­u­la­tion (tDCS) is an inves­tiga­tive modal­i­ty for major depres­sive dis­or­der (MDD) that has shown some promis­ing results. Though it has a while before it is approved by the US Food and Drug Admin­is­tra­tion, clin­i­cians and patients have been clam­or­ing for an effec­tive treat­ment for MDD that is not asso­ci­at­ed with harm­ful adverse effects. [Read more…] about Tran­scra­nial Direct Cur­rent Stim­u­la­tion shows ear­ly promise to ame­lio­rate depres­sion, espe­cial­ly if com­bined with oth­er ther­a­pies and dosage optimized

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: depression, efficacy, Major Depressive Disorder, MDD, meta-analysis, NICE, pharmacotherapy, tDCS, Transcranial-direct-current-stimulation, US Food and Drug Administration

FDA clears deep transcranial magnetic stimulation device to treat obsessive-compulsive disorder

September 14, 2018 by SharpBrains

Brain­sWay’s Brain Stim­u­la­tion Device Receives FDA Approval to Treat Obses­sive-Com­pul­sive Dis­or­der (IEEE Spectrum):

“In 2013, Jerusalem-based Brain­sWay began mar­ket­ing a new type of brain stim­u­la­tion device that uses mag­net­ic puls­es to treat major depres­sive disorder.

Now, thanks to pos­i­tive results in a study of 100 patients, the com­pa­ny has received approval from the U.S. Food and Drug Admin­is­tra­tion (FDA) to mar­ket the device for a sec­ond psy­chi­atric condition—obsessive-compulsive dis­or­der (OCD) [Read more…] about FDA clears deep tran­scra­nial mag­net­ic stim­u­la­tion device to treat obses­sive-com­pul­sive disorder

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: brain-stimulation, BrainsWay, deep transcranial magnetic stimulation, Deep-TMS, device, FDA, Major Depressive Disorder, obsessive-compulsive disorder, tDCS, Transcranial-direct-current-stimulation

Systematic evidence review finds cognitive behavioral therapy as effective as antidepressant medicines in treating depression

April 4, 2016 by SharpBrains

mentalhealthtreatmentsDepres­sion: Treat­ment Beyond Med­ica­tion (The Dana Foundation):

“Major depres­sive dis­or­der affects near­ly 7 per­cent of peo­ple in the US aged 18 and up, accord­ing to the Depres­sion and Bipo­lar Sup­port Alliance. Those who seek treat­ment will most like­ly be pre­scribed a sec­ond-gen­er­a­tion anti­de­pres­sant med­ica­tion such as a selec­tive sero­tonin reup­take inhibitor (SSRI), tri­cyclic anti­de­pres­sant (TCA), or a monoamine oxi­dase inhibitor (MAOI). Some recent stud­ies, though, [Read more…] about Sys­tem­at­ic evi­dence review finds cog­ni­tive behav­ioral ther­a­py as effec­tive as anti­de­pres­sant med­i­cines in treat­ing depression

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health Tagged With: antidepressants, biomarkers, clinical, cognitive-behavioral-therapy, computerized psychotherapies, depression, depression treatments, Major Depressive Disorder, medication, non-pharmacologic, pharmacologic, psychotherapies

Next Page »

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 12,516 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2023 SharpBrains. All Rights Reserved - Privacy Policy